Companies › ReAlta Life Sciences
1 active drug program in 3 registered trials: 3 Phase 2; Immunology, Other, Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RLS-0071 Novel peptide | – | Phase 2 | Acute Exacerbation of Chronic Obstructive Pulmonary Disease; Steroid Refractory GVHD; Hypoxic-Ischemic Encephalopathy | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06175065 | RLS-0071 | Phase 2 | Acute Exacerbation of Chronic Obstructive Pulmonary Disease | Respiratory | Jun 2025 |
| NCT06343792 | RLS-0071 | Phase 2 | Steroid Refractory GVHD | Immunology | Dec 2026 |
| NCT05778188 | RLS-0071 | Phase 2 | Hypoxic-Ischemic Encephalopathy | Other | Dec 2026 |
No annotated target.
–
Prana Therapies Enveda Therapeutics Clarent Biopharma Optinose US Kymera Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.